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Objec:ves
• To discuss the historical arguments for a
diagnos/c category.
• Why are we raising this issue now?
• Does schizoaﬀec/ve disorder qualify as a
diagnosis for any classiﬁca/on?

Prevalence of mood symptoms across longitudinal
course of schizophrenia ( from diﬀerent studies)

Depression occurs across the course of
schizophrenia

Emergence of new diagnosis:
Jacob kasonin 1933
• Jacob Kasonin 1933:
• Rela:vely good pre‐illness
psychosocial adjustment
• Abrupt emo:onal
presenta:on
• Less social withdrawal or
passivity
•

A shorter course of illness

• A rela:vely good recovery

The Third
Psychosis:
Schizoaﬀec/ve
Disorders

Aﬀec/ve
Disorder

Schizophrenia

Posi:oning of schizoaﬀec:ve psychosis
•
•
•
•
•
•
•

Leonard 1961 :
third psychosis”
ICD 9 :
subsumed under schizophrenia
In RDC :
it was kept separate en/ty
Separate en/ty was con/nued up to DSM‐III R
In DSM IV :
with schizophrenic disorder
DraQ of ICD 10 in 1986: with aﬀec/ve disorder
Final draQ of ICD 10 : placed alongside of
schizophrenic disorder

DSM
DSM IV and ICD 10 both insist on exclusion
An uninterrupted period of illness during which,
at some :me there is either:
(1) A Major Depressive Episode

•

(2) A Manic Episode, or

Schizoaﬀec:ve
– Bipolar
– Depressive

(3) A Mixed Episode concurrent with symptoms that meet
(4) Criterion A for Schizophrenia.
Utilizes - Categorical approach
Two major neurobehavioral dimensions:
thought &

Mood

Schizoaﬀec:ve disorders: ICD 10
• Episodic disorders in which both aﬀec:ve and schizophrenic
symptoms are prominent but
• do not jus:fy diagnosis of either
• schizophrenia or depressive or manic episodes.
• Mood‐incongruent psycho:c symptoms in aﬀec:ve
disorders : DO NOT

Schizoaﬀec:ve disorders: ICD 10
F25.0

Schizoaﬀec:ve disorder, manic type

• F25.1

Schizoaﬀec:ve disorder, depressive type

• F25.8

Other schizoaﬀec:ve disorders

• F25.9

Schizoaﬀec:ve disorder, unspeciﬁed

Commonly seen co‐occurrence of symptoms:

Representa:on of depressive cluster & psycho:c cluster in rela:on to its appearance
during psycho:c episode.

A psycho/c episode

Psychosis
domain

Depressive
domain

The term should not be applied to patients who
exhibit schizophrenic symptoms and affective
symptoms only in different episodes of illness.

Superimposed secondary depression is
not a schizoaﬀec:ve disorder

Superimposed
depression

Other conditions in which affective symptoms are
superimposed on a pre-existing schizophrenic illness,
or co-exist or alternate with persistent delusional
disorders of other kinds, are classified under F20F29.

Severity

Within same episode

Duration

Booth clusters of psychosis and depression
should occur within same episode with
reasonable equivalence in severity and duration
for a diagnosis of SAD

DSM-IV:
presence of mood symptoms for
Substantial portion
of total duration of the episode for diagnosis of SAD is
required.

2 weeks

Schizoaffective
Persistence of psychotic symptoms for at least 2 weeks beyond the
resolution of mood symptoms: DSM –III-R

Schizoaffective

diagnosis of SAD should be made
only when both definite schizophrenic and
definite affective symptoms are
prominent simultaneously, or
within a few days of each other,
within the same episode of illness,
and when, as a consequence of this, the episode of illness does not meet
criteria for either schizophrenia or a depressive or manic episode.

Schizoaffective

It is common, for example, for a schizophrenic patient to
present with depressive symptoms in the aftermath of a
psychotic episode.
The ‘Post-psychotic depression or mania is NOT SAD

Schizoaffective

1-2 weeks

Schizoaffective

Recurrent
Schizoaffective

Some patients have recurrent schizoaffective episodes, which
may be of the manic or depressive type or a mixture of the two.
In this case, schizoaffective disorder is the appropriate
diagnosis.

Bipolar affective

Others have one or two schizoaffective episodes interspersed
between typical episodes of mania or depression.
The occurrence of an occasional schizoaffective episode does
not invalidate a diagnosis of bipolar affective disorder or
recurrent depressive disorder if the clinical picture is typical in
other respects

Does schizoaffective disorder
really exist?
middle point of a continuum
between SCH and MD.
J Affect Disord. 2008 Mar

Schizoaﬀec/ve disorder merges schizophrenia and bipolar disorders as
one disease‐
‐

There is no schizoaﬀec:ve disorder
Curr Opin Psychiatry. 2007 Jul;.

Schizoaffective disorders are
psychotic mood disorders;
there are no schizoaffective
disorders.
Psychiatry Res. 2006 Aug

Why is this argument being
made?

Objec:ons & DSM V
• Subgroup of schizophrenia
• Severe form of mood disorder
(MMD or BAD)
• Co‐occurrence of the two
• Diagnos:c instability inﬂuences
outcome & prognosis

Objec:ons & DSM V
• Lack of consensus
– Conceptually
– Clinical aspects
• Dimensional approach recognize
disturbance
– thought &
– mood
– Would avoid categorizing into either
mood or psychosis

Diagnos:c instability

• Poor inter‐rater reliability for
SAD ( Mario 2000),
• 0% reconﬁrma:on of discharge
diagnosis of SAD ( Vollmer‐
Larsen 2006)

Diagnos:c instability
• Schwartz et al stability of diagnosis at 6 &
24 months
– 92% schizophrenia
– 83% Bipolar disorder
– 74% major Depression
– 44% psychosis NOS
– 36% Schizoaﬀec:ve
– 27% Brief psycho:c Disorder

‘Diagnos:c Validity of Schizoaﬀec:ve disorders’
Shrivastava A, Rao, S. IJP.1997

‘Diagnos:c Validity of Schizoaﬀec:ve
disorders’
Shrivastava A, Rao, S. IJP.1997

• 82.5% pa:ents diagnosis of
schizoaﬀec:ve disorder in Changed at
the endpoint of 2 years
• 70% qualify for a diagnosis of
schizophrenia in 2 years :me

Co morbidity in Categorical approach would need to
be coded on diﬀerent axis
Schizoaﬀec:ve
PTSD: 50%

Bipolar mood
disorder

OCD 30%

Major mood
disorder
Schizophrenia

Utility of diagnosing these condition away
from main disorder is questionable
Byerly, 2004, 2005, Strauss et al 2006

Does it qualify as a diagnosis to
be in any classiﬁca/on?
Literature review also failed to indicate a clear cut dis/nc/on between
SAD and SCH or MD.
DISCUSSION: Present analysis indicated that
1. SAD cannot be interpreted as atypical forms of SCH or MD.
2. SAD also does not appear to represent a SCH and MD comorbidity or
3. yet an independent mental disorder.
4. It is argued that SAD might cons/tute a heterogeneous group
composed by both SCH and MD pa/ents or
5. a middle point of a con/nuum between SCH and MD.

J Affect Disord. 2008 Mar

Criteria for classiﬁca:on
Evidence
Included

•
•
•
•
•

Origin
Manifesta:on
Course
Outcome
Response to treatment

Excluded

•
•
•
•
•
•
•

Severity
Co morbidity
Sub‐types
Ae/opathological
Biological
Gene/cs
Heritability
33

3
3

Categorical approach

Depression

Schizophrenia

Independent origin , course, outcome ,
response to treatment

3
4

Categorical approach

Mood

Psycho/c
syndromes
Schiz

Third
psychosis

3
5

Dimensional approach
Spectrum

3
6

The spectrum of psychosis
Risk factors
Family history of
aﬀec:ve disorder
Social adversity
Female gender

Risk factors
Family history of schizophrenia
Obstetric complica:on
Childhood dysfunc:on
Male gender

Aﬀec:ve psychosis
Acute

Neurodevelopmental
impairment

Chronic
Spectrum of psychosis

Schizophrenia and spectrum Disorder:
Genetic phenomenology
Decreasing Genetic Risk
for schizophrenia in
Relatives

Schizophrenia

Increasing Genetic Risk
for affective Disorders
and alcoholism in Relatives

1%

1%

1%
1%
Affective
schizophrenia

1%
0.7%

Core/ deficit
Schizophrenia

1%
1%
Schizotypal
Personality
Disorder

Current Evidence

Popula/on
Prevalence

Related
Symptom
Cluster

Common neurobiological origin of
‘Severe’ psychosis”

3‐4%

Bipolar
Spectrum

Bipolar Disorder: type I

2%

Depressive
spectrum

Unipolar
Depression with
psycho/c features

0.7‐1.4%

Schizophrenia
spectrum

Schizophrenia

0.5‐0.7%

An Endophenotype of Schizophrenia
Environmental
unmasking

Genotype

Environmental
Suscep/bility
Gene

Psychological
Unmasking
Modiﬁer Genes

Mul:ple
Endophenotypes

Social Unmasking

Life style issue

Schizophrenia spectrum

Behavioral Traits‐
Correlates

Risk factors
Genotype

Brain Vulnerability

Essen/al E/ological factors

15/03/2008

40

Current posi:on & Evidence
to drop from DSM V
Reviewing and contras/ng categorical &
dimensional approach to approach
Clinical descrip/on
Neurobiology
Treatment.

Ae:ologic overlap between schizophrenia,
schizoaﬀec:ve disorder, and bipolar disorder
• Growing evidence
•
• Inves/gated ‘magnitude of •
the overlap’ over a 35‐year
period based on the en/re •
Danish popula/on. followed
from 1970 to 2006.
•
• A register‐based prospec/ve •
cohort study > 2.5 million
persons born in Denmark •
•
aQer 1954.
• A new comorbidity index, CI

Schizophrenia N = 12,734,
Bipolar disorder N = 4,205
with
Schizoaﬀec/ve disorder N
= 1,881
SAD & BD
= 103.
SAD & SCH = 80
SCH & BD = 20.
Similar large indexes were
found for men as well

J Clin Psychiatry. 2009 Jun 16. Laraun TM et al

Ae:ologic overlap between schizophrenia,
schizoaﬀec:ve disorder, and bipolar disorder

• Substan:al comorbidity index
• This study supports the existence of an
overlap between bipolar disorder and
schizophrenia and thus challenges the strict
categorical approach used in both DSM‐IV
and ICD‐10 classiﬁca:on systems.

J Clin Psychiatry. 2009 Jun 16. Laraun TM et al

Outcome is beler than schizophrenia and worse than
mood disorder:
Benabarre 2001, del Rio 1990, 1992

Symptoma/c & long
term func/on is
stable like
schizophrenia
Tsuang 1993, Harrow
2000, Benabarre
2001

Beker symptoma/c
and func/onal
outcome of SAD<
MMD< SCHIZ:
Marneros 1989,
Tohen 2000

Long‐term outcome:
Is it any diﬀerent
• 1934 and 1944 : 30‐ to 40‐year outcome
study.
• Pa:ents with schizoaﬀec:ve disorders had a
signiﬁcantly beler outcome
• A signiﬁcantly poorer outcome than those
with aﬀec:ve disorders and surgical
condi:ons.
Arch Gen Psychiatry. 1979 Nov;36(12):1302-4. Long-term outcome of major psychoses. II. Schizoaffective disorder compared with schizophrenia,
affective disorders, and a surgical contro group Tsuag MT Dempsey GM

Long‐term outcome:
Is it any diﬀerent
• 4‐5 years aQer hospitaliza/on
• Overall, schizoaﬀec/ve pa/ents
showed some similari/es to both
schizophrenic and bipolar manic
pa/ents.
• Somewhat beker overall post hospital
func/oning.
• LS Grossman, M Harrow, JF Goldberg and CG Fichtner
1991

Response to Treatment:
Does it dis:nguish?
• Treatments echo dimensional approach
• There is no speciﬁc treatment
• Symptom‐guided treatments are advocated
• Response to any approach of treatment does not
dis:nguish this diagnos:c en:ty
• SAD: beler responsive schizophrenia
• Poor responding mood disorder

Epidemiology
As prevalent as schizophrenia but less than Bipolar
disorder
Similar to SCH, as per one
criteria: ‘informa:on
processing’
Less than SCH if 2 Criteria
informa:on processing +
emo:onal regula:on

•
•
•
•
•
•

Epidemiology
As prevalent as schizophrenia but less than Bipolar
disorder
Prevalence < schizophrenia as DSM‐IV TR
Life :me prevalence: 0.2%‐1.1%(Zarate 1997,
Marneros 2003)
9% among hospitalized psychiatric inpa:ents( Scully
2004)
SAD & SCH half as common as Bipolar I ( Benaberre
2001)
Rare among psycho:c children (Werry 1991)
Diagnos:c challenge in Co morbidity of LD, SUD
( Freidlander 2004, Malla 2000)

Age of onset
Gender:
Broad range
F < M : 2/3:1/3
1/3 between 25‐35 years
1/3 Prior to 25
1/3 aQer 35
Early age onset: SAD with Depressed & Bipolar
subtype
• Adult onset: ‘pure’ Mood disorder
•
•
•
•
•

Angst 1995, Dell’osso 1993,

Neurobiology

studies are 1‐or‐2 domain speciﬁc

• All 3 are manifesta:on of disturbance in
several domains of NB
• Neuropsychology
• Neuroimaging,
• Electrophysiological
• Neurochemical
• Gene:c

Neurobiology

studies are 1‐or‐2 domain speciﬁc

‘dysfunc:on of
informa:on processing’

Emo:onal regula:on

‘indis:nguishable’ from any
other psychiatric disorder

Indis:nguishable from mood
disorder

Neuropsychology : 16 studies
• Changes similar to schizophrenia
• Impairments in frontally mediated
cogni:on, including
– working memory,
– altera:on alen:on,
– informa:on recall,
– category genera:on,
– abstrac:on, Motor
– planning

Neuropsychology : 16 studies
• Beler performance in 2 studies ( Glodstein
2005, Strip 2005)
• SCH itself is heterogeneous
• Sub typing of SCH based on domains of
neurobehavioral dysfunc:on may result in
dis:nct subgroup.
• Basic dysfunc:on : Cogni:on‐ informa:on
processing

Structural neuroimaging:
CT & MRI: 12 studies.
• Reduc:on in cerebral volumes par:cularly
temporal & frontal regions
• Both white & grey maler loss
• Most consistent area of abnormality :
hippocampus & parahymppocampal gyri
• Indis:nguishable from either SCH or Bipolar
• Dis:nguishable from Normal controls
• Subtle diﬀerences are present

Neurochemical: 16 studies
• CSF or Serum NT or metabolite
• ‘Similar palern of NT abnormality in SCH, SAD &
BAD’ (Meltzer 1984)recent studies also observed
‘no diﬀerence’
• Neurochemistry is symptom speciﬁc rather than
disease or syndrome speciﬁc
NE, PGE1, PGE1
Adenylcyclase &
platelet 5HT level –
similar in SAD & SCH

Platelet 5 Ht proﬁle like
bipolar disorder

Neuroendocrine:

Evidence for a neuromodulatory role for TRH

CSF thyrotropin‐releasing hormone concentra/ons diﬀer in
pa/ents with schizoaﬀec/ve disorder from pa/ents with
schizophrenia or mood disorders, :
Charles B. Nemeroﬀc Journal of Psychiatric Research
Volume 35, Issue 5, September‐October 2001,

Gene:cs
• Studies have generally failed to dis:nguish SAD
from either SCH or BAD on the basis of gene:c
underpinnings
• DISC 1 abnormality on Chromosome 1q42
• A role in neurodevelopment process
• Preferen:ally expressed in forebrain.
• DISC 1 is regarded as risk factor for both SCH &
bipolar

Familial
• To test whether schizoaﬀec:ve disorder is a variant
•

Number of ADSA and SASC pairs were compared
against the expected numbers.

• No signiﬁcant diﬀerences were found,
• Suggests that schizoaﬀec:ve disorder is gene:cally
heterogeneous,
• With at least two subtypes,
– one a variant of aﬀec:ve disorder,
– the other a variant of schizophrenia

Summary
Current evidence in
favor of
Schizoaﬀec/ve

Clinical‐ Course &
Outcome Nega/ve

Neurochemistry:
Equivocal

Neuroimaging:
Nega/ve

Gene/cs: Nega/ve

Treatment Response:
Nega/ve

Kraepelin is not dead
“It is increasingly becoming clear
that we can not distinguish
satisfactorily between these two
illnesses and this brings home the
suspicion that our formulation of
the problem may be incorrect”
Kraepelin .E.

Future recommenda:ons.
• Schizoaﬀec/ve disorder is a prototypic boundary
condi/on
• Epitomizes the pipalls of the current categorical
classiﬁca/on system.
• Future revisions to the DSM should consider:
• (i) SAD is a co morbid set of symptoms that occur as
a by‐product of two separate disorders (SCZ and BD)
or, that
• (ii) SAD exists as the mid‐point on a con/nuum
between SCZ and BD,
Malhi GS, Green M, Fagiolini A, Peselow ED Kumari V
Bipolar Disord. 2008 Feb;10(1 Pt 2):215-30

DSM V
• Incorpora/on of these two disorders onto one
dimension may be a suitable alterna/ve.
• Hence the category SAD should be omiked in
future revisions of DSM, allowing the
development of meaningful nomenclature
that…..
• …..rests upon further rigorous inves/ga/on of
diﬀerences and similari/es between disorders.

Management of Mood
symptoms in schizophrenia:
Beyond Diagnos:c ambiguity.

• Pharmacological management of Mood
symptoms and that of ‘suicidality’ in
schizophrenia goes hand –in‐hand.
• Eﬀec:ve strategy
• Op:mizing an:psycho:c treatment and atypical
an:psycho:cs prove to be most eﬀec:ve
• Adjunc:ve an:depressants may be useful for
pa:ents who are not acutely ill
• Careful longitudinal assessment is required to
ensure iden:ﬁca:on of primary mood disorders

How to treat schizoaﬀec:ve disorder?..
Cochrane review June 2009
•
•
•
•
•
•
•

Aim: to review treatment studies for schizoaﬀec:ve disorder and draw
conclusions for clinical decision making.
Method: : Thirty‐three studies , 14 randomized controlled trials.
The studies reviewed do not permit consistent recommenda:ons as to
whether SAD should be treated primarily with
an:psycho:cs,
mood stabilizers or
combina:ons of these drugs.
The relevance of diverse subtypes .. for treatment recommenda:ons is
unclear.
Conclusion:. The lack of conclusive recommenda:ons is related to issues
of nosological status, plurality of diagnos:c criteria and validity of the
concept.
Jäger M, Becker T, Weinmann S, Frasch K.Department of Psychiatry II, Ulm University, Günzburg, : Treatment of schizoaﬀecJve disorder
‐ a challenge for evidence‐based psychiatry. Acta Psychiatr Scand. 2009 Jun 30.

Current evidence: An: Depressant Drugs
Use of antidepressant drugs in schizophrenic patients with depression
Encephale. 2006

• The results provide weak evidence for the eﬃcacy
of an:depressants in pa:ents with schizophrenia
and depression.
• The only SSRI tested in the treatment of
depression in schizophrenic pa:ents is sertraline.
• In meta‐analysis, No diﬀerence between the 2
treatment groups was demonstrated

Electroconvulsive therapy for schizophrenia
2009 The Cochrane Collabora:on. 26 trials with 50 reports.

1. Eﬃcacy.
1. ECT is compared with placebo
or sham ECT,
2. ECT resulted in less relapses in
the short term and a greater
likelihood of discharge
3. No signiﬁcant drop out
compared with sham ECT .

2. Sustain the eﬃcacy.
1. No evidence ‐ advantage is
maintained ‐ medium to long
term.

3. Combina:on APD
1. Compared with an/psycho/c
drug ‐ favour the medica/on
group
2. Limited evidence ‐ ECT
combined with an/psycho/c
drugs > greater improvement
than with an/psycho/c drugs
alone.
3. When con/nua/on ECT was
added to an/psycho/c drugs,
the combina/on was superior
to the use of an/psycho/cs
alone.

Prathap Thyhan , Schizophrenia Cochrane group 2009.

Electroconvulsive therapy for schizophrenia
2009 The Cochrane Collabora:on. 26 trials with 50 reports.

4.Memory
1. Very limited data indicated that visual memory might decline aQer ECT
compared with sham ECT
2. Verbal memory tests were equivocal.
3. One small study suggested more memory impairment with ECT combined
with an/psycho/cs than with an/psycho/cs alone , though this proved
transient.

5. Type
1. Unilateral and bilateral ECT were equally eﬀec/ve in terms of global
improvement

6.Numbers.
1. One trial showed a signiﬁcant advantage for 20 treatments over 12 treatments
for sustenance of remission

Current evidence : Mood Stabilizers
•
•
•
•
•
•
•

Lithium
Carbamezapine
Valproic acid
Lamotregene
Toperamate
Gabapen/ne
Calcium channel
blockers

Carbamazepine for schizophrenia
2009 The Cochrane Collabora:on,
Studies 10, N= 258
Based on currently available
randomized trial‐derived evidence,
carbamazepine cannot be
recommended
Valproate for schizophrenia
2009 The Cochrane Collabora:on,
7 studies, 6 RCT, N=519
There is some evidence for posi:ve
eﬀects on
aggression and
tardive dyskinesia,

Adding Lithium or An:convulsants to An:psycho:cs for the
Treatment of Schizophrenia: Useful Strategy or Exercise in
Fu:lity? June 2009 JCP

• Lithium is perhaps the best‐known mood stabilizer,
• Although early studies showed adjunc:ve lithium
to be some‐ what useful, later and beler‐designed
trials did not.
• A Cochrane review of RCTs concluded that, despite
some evidence suppor:ng the eﬃcacy of lithium
augmenta:on among 11 studies tes:ng this,
• Overall results were inconclusive.
Leslie Citrome, M.D., M.P.H. ,AMERICAN
SOCIETY OF CLINICAL
PSYCHOPHARMACOLOGY

Adding Lithium or An:convulsants to An:psycho:cs for the
Treatment of Schizophrenia: Useful Strategy or Exercise in
Fu:lity? June 2009 JCP
Before Lithium N=310
With Lithium N=310
First Year aQer Lithium N=185
8

Recent Years aQer Lithium N=133
7.2

6
4
2
0

2.1

2.15
0.25

Suicide akempt/100 pa/ent/year
Meltzer e Baldessarini, 2003

Are atypical neurolep:cs
mood stabilisers?
•

Are they eﬀec/ve beyond psycho/c aﬀec/ve states?

•

Are they eﬀec/ve against the depressive phase of bipolar
disorder?

•

Do they induce mania?

•

Do they work in mixed states?

•

Do they work in rapid cycling?

•

Can they prevent suicide?

How do we explain?
Why do Atypical an:psycho:cs have
An:depressant ac:on?
A: Regional distribu:on of 5‐HT
System in the Brain??
B. Eﬀect of metabolites
(norque:apine)

Rela:ve Eﬃcacy of AAPD for mood symptoms and
suicidality in Schizophrenia
Clozapine and Suicide

Itersept
CATIE
SOHO
Cultass
BORAS
Phase III trials
Individual studies,
RCT

•
•
•
•
•
•
•
•

Clozapine
Olanzapine
Aripiprazole
Que/apine
Amisulpiride
Ziprasidone
Paliperidone
Risperidone

Increasing
efficacy

Does que:apine have mood altering
proper:es?

• A combina/on of Non‐que/apine and que/apine has been
found to have an/depressant property in MMD, thus FDA
approved now.
• Supported by a data base of 1900 pa/ents.
•

An ability to elevate mood while controlling psychoses would
be helpful in the treatment of post‐psycho/c and bipolar
depression.

• Its clinical importance in the control of manic episodes, for
which atypical an/psycho/cs are used increasingly, is
uncertain.
1. De Nayer et al. Int J Psych Clin Pract 2003;7:59-66. shows efficacy on CDSS

Preven:on of Suicide in Psycho:c Disorders:
General principles and strategies.
What is specific to suicide in
schizophrenia disorder? Demographic,
clinical and behavioural dimensions.
Elevated levels of impulsive-aggressive
personality traits, and behaviours
( Schizophrenia research 2008)

Post‐diacharge suicide is high
• Term ‘Discharge’ is a misnomer.
It is actually ‘transfer of Care from Hospital to
Community’
It is a dynamic Process’ .
Review: Assessment, Outcome, Care Plan,
Discharge Plan, Risk Management & Transfer of care

Documentation

Conclusions:
Schizoaﬀec:ve disorders.

There are many unanswered ques:ons

• Schizoaﬀec:ve disorder is a severe psycho:c
disorder with disability, burden and
complica:ons.
• Schizoaﬀec:ve Disorder is an inconsistent
condi:on and does not deserve an
independent diagnosis
• We are moving towards unitary theory for
single‐severe‐psycho:c‐disorder, based on
clinical and biological evidences

Conclusions:
Schizoaﬀec:ve disorders.

There are many unanswered ques:ons

• Treatment appears inadequate and unclear,
but op:mizing atypicals APD appears best
op:on.
• Que:apine is an eﬀec:ve and approved
atypical APD for MMD, Bipolar &
schizophrenia

